NDAORALTABLET
Approved
Jun 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
6/8 — Strong
EXFORGE (amlodipine besylate and valsartan) by Novartis is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 2007.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXFORGE is a fixed-dose combination tablet containing amlodipine besylate (a calcium channel blocker) and valsartan (an angiotensin II receptor blocker) indicated for hypertension management. It works by dual mechanism: amlodipine relaxes blood vessels through calcium channel inhibition while valsartan blocks angiotensin II receptors, both reducing blood pressure. This combination targets patients requiring multi-drug antihypertensive therapy.
$0.002BPart D
LOE ApproachingDeclining
Limited commercial growth trajectory with modest Part D spending; team focus likely shifting to managed decline and generic transition strategy.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers
Started Jul 2012
51 enrolled
Healthy Male Volunteer
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
Started May 2010
564 enrolled
Hypertension
Career Relevance
EXFORGE currently shows zero linked job postings, reflecting its late-lifecycle status and declining commercial priority at Novartis. Career opportunities on this brand are limited to specialist roles in managed decline, generic transition, and existing patient support.
Worked on EXFORGE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.